Science & Technology
Identification of therapeutic molecules to treat amphetamine use disorders using our DNA-encoded library (DEL) technology
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R43DA061909-01
Award Ceiling
$398K
Award Floor
$398K
Close Date
Jun 30, 2026
107 days leftTotal Funding
$398K
Expected Awards
1
Posted Date
Jul 1, 2025
Cost Sharing Required
No
Grants.gov ID
sbir-1R43DA061909-01
Description
SBIR Phase Phase I award: "Identification of therapeutic molecules to treat amphetamine use disorders using our DNA-encoded library (DEL) technology" awarded to JiLLiON Therapeutics Inc. in New York, New York. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $398,093. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses, HUBZone businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.